Alec Stranahan
Stock Analyst at B of A Securities
(0.64)
# 3,703
Out of 4,818 analysts
30
Total ratings
35%
Success rate
-32.47%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Alec Stranahan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BEAM Beam Therapeutics | Upgrades: Buy | $42 | $19.89 | +111.21% | 1 | Mar 28, 2025 | |
| YMAB Y-mAbs Therapeutics | Maintains: Neutral | $14 → $12 | $4.14 | +189.86% | 5 | Mar 5, 2025 | |
| CADL Candel Therapeutics | Initiates: Buy | $15 | $4.76 | +215.13% | 1 | Feb 7, 2025 | |
| DAWN Day One Biopharmaceuticals | Maintains: Buy | $28 → $25 | $7.46 | +235.12% | 4 | Jan 7, 2025 | |
| CRBU Caribou Biosciences | Maintains: Buy | $13 → $11 | $0.84 | +1,202.24% | 1 | Jan 7, 2025 | |
| ERAS Erasca | Upgrades: Buy | $5 | $1.43 | +249.65% | 2 | Jan 7, 2025 | |
| CATX Perspective Therapeutics | Downgrades: Neutral | $24 → $6 | $2.34 | +156.41% | 2 | Nov 25, 2024 | |
| RVMD Revolution Medicines | Maintains: Buy | $48 → $55 | $37.56 | +46.43% | 3 | Jul 16, 2024 | |
| NVAX Novavax | Maintains: Neutral | $12 → $18 | $7.47 | +140.96% | 3 | Jun 14, 2024 | |
| KRYS Krystal Biotech | Maintains: Buy | $118 → $140 | $166.37 | -15.85% | 3 | May 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $42 | $10.87 | +286.38% | 1 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $5 → $6 | $39.49 | -84.81% | 2 | Dec 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $60 → $5 | $0.78 | +541.03% | 1 | Dec 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $45 | $41.21 | +9.20% | 1 | Dec 1, 2022 |
Beam Therapeutics
Mar 28, 2025
Upgrades: Buy
Price Target: $42
Current: $19.89
Upside: +111.21%
Y-mAbs Therapeutics
Mar 5, 2025
Maintains: Neutral
Price Target: $14 → $12
Current: $4.14
Upside: +189.86%
Candel Therapeutics
Feb 7, 2025
Initiates: Buy
Price Target: $15
Current: $4.76
Upside: +215.13%
Day One Biopharmaceuticals
Jan 7, 2025
Maintains: Buy
Price Target: $28 → $25
Current: $7.46
Upside: +235.12%
Caribou Biosciences
Jan 7, 2025
Maintains: Buy
Price Target: $13 → $11
Current: $0.84
Upside: +1,202.24%
Erasca
Jan 7, 2025
Upgrades: Buy
Price Target: $5
Current: $1.43
Upside: +249.65%
Perspective Therapeutics
Nov 25, 2024
Downgrades: Neutral
Price Target: $24 → $6
Current: $2.34
Upside: +156.41%
Revolution Medicines
Jul 16, 2024
Maintains: Buy
Price Target: $48 → $55
Current: $37.56
Upside: +46.43%
Novavax
Jun 14, 2024
Maintains: Neutral
Price Target: $12 → $18
Current: $7.47
Upside: +140.96%
Krystal Biotech
May 25, 2023
Maintains: Buy
Price Target: $118 → $140
Current: $166.37
Upside: -15.85%
May 19, 2023
Initiates: Buy
Price Target: $42
Current: $10.87
Upside: +286.38%
Dec 29, 2022
Maintains: Underperform
Price Target: $5 → $6
Current: $39.49
Upside: -84.81%
Dec 2, 2022
Downgrades: Underperform
Price Target: $60 → $5
Current: $0.78
Upside: +541.03%
Dec 1, 2022
Initiates: Buy
Price Target: $45
Current: $41.21
Upside: +9.20%